Stevanato Group (87N) Stock Forecast & Price Target

3 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

87N Analyst Ratings

Strong Buy

4 Buy

1 Hold

0 Sell

Based on 5 analysts giving stock ratings to

Stevanato

Group

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

87N Stock 12 Month Forecast

Average Price Target

€19.73

▲(14.69% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Stevanato Group in the last 3 months. The average price target is €19.73 with a high forecast of €22.54 and a low forecast of €16.48. The average price target represents a 14.69% change from the last price of €17.20.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"€10","23":"€23","13.25":"€13.25","16.5":"€16.5","19.75":"€19.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":22.54486416,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€22.54</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.72675614,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€19.73</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16.47509304,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€16.48</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10,13.25,16.5,19.75,23],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.2,17.611143396923076,18.022286793846153,18.43343019076923,18.844573587692306,19.255716984615383,19.666860381538463,20.078003778461536,20.489147175384616,20.900290572307693,21.31143396923077,21.722577366153846,22.133720763076923,{"y":22.54486416,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.2,17.394365856923077,17.588731713846155,17.78309757076923,17.977463427692307,18.171829284615384,18.366195141538462,18.560560998461536,18.754926855384614,18.94929271230769,19.14365856923077,19.338024426153844,19.53239028307692,{"y":19.72675614,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.2,17.144237926153846,17.088475852307692,17.032713778461538,16.976951704615384,16.92118963076923,16.865427556923077,16.809665483076923,16.75390340923077,16.698141335384616,16.642379261538462,16.58661718769231,16.530855113846155,{"y":16.47509304,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":21.522,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.33,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.12,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.522,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.23,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.337,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.052,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.753,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.757,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.248,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.942,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.2,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€22.54

Average Price Target€19.73

Lowest Price Target€16.48

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Kallum Titchmarsh

Morgan Stanley

€16.48

Hold

-4.21%

Downside

Assigned

08/03/26

Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (NASDAQ: ASND), Moderna (NASDAQ: MRNA) and Stevanato Group (NYSE: STVN)

Chad Wiatrowski

TD Cowen

€21.68

Buy

26.03%

Upside

Reiterated

07/14/26

TD Cowen Keeps Their Buy Rating on Stevanato Group (STVN)

Matt Larew

William Blair

―

Buy

―

Reiterated

07/09/26

Analysts Offer Insights on Healthcare Companies: Stevanato Group (NYSE: STVN) and Siemens Healthineers AG (Other OTC: SEMHF)

Patrick B Donnelly

Citi

€22.54

Buy

31.07%

Upside

Reiterated

07/08/26

Analysts Offer Insights on Healthcare Companies: Stevanato Group (NYSE: STVN) and ARS Pharmaceuticals (NASDAQ: SPRY)

Michael Polark

Wolfe Research

€18.21

Buy

5.87%

Upside

Initiated

06/01/26

Stevanato Group assumed with an Outperform at Wolfe ResearchStevanato Group assumed with an Outperform at Wolfe Research

Paul Knight

KeyBanc

€32.08→€27.75

Buy

61.32%

Upside

Assigned

03/05/26

Analysts Offer Insights on Healthcare Companies: Stevanato Group (NYSE: STVN), Stryker (NYSE: SYK) and Xencor (NASDAQ: XNCR)

Michael Ryskin

Bank of America Securities

€26.01→€24.28

Buy

41.16%

Upside

Reiterated

03/04/26

Stevanato Group price target lowered to $28 from $30 at BofAStevanato Group price target lowered to $28 from $30 at BofA

David Windley

Jefferies

€19.94→€15.17

Hold

-11.78%

Downside

Reiterated

02/10/26

Stevanato Group price target lowered to $17.50 from $23 at JefferiesStevanato Group price target lowered to $17.50 from $23 at Jefferies

Dan Leonard

RBC Capital

€22.54→€24.28

Hold

41.16%

Upside

Reiterated

08/06/25

UBS Sticks to Its Hold Rating for Stevanato Group (STVN)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Kallum Titchmarsh

Morgan Stanley

€16.48

Hold

-4.21%

Downside

Assigned

08/03/26

Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (NASDAQ: ASND), Moderna (NASDAQ: MRNA) and Stevanato Group (NYSE: STVN)

Chad Wiatrowski

TD Cowen

€21.68

Buy

26.03%

Upside

Reiterated

07/14/26

TD Cowen Keeps Their Buy Rating on Stevanato Group (STVN)

Matt Larew

William Blair

―

Buy

―

Reiterated

07/09/26

Analysts Offer Insights on Healthcare Companies: Stevanato Group (NYSE: STVN) and Siemens Healthineers AG (Other OTC: SEMHF)

Patrick B Donnelly

Citi

€22.54

Buy

31.07%

Upside

Reiterated

07/08/26

Analysts Offer Insights on Healthcare Companies: Stevanato Group (NYSE: STVN) and ARS Pharmaceuticals (NASDAQ: SPRY)

Michael Polark

Wolfe Research

€18.21

Buy

5.87%

Upside

Initiated

06/01/26

Stevanato Group assumed with an Outperform at Wolfe ResearchStevanato Group assumed with an Outperform at Wolfe Research

Paul Knight

KeyBanc

€32.08→€27.75

Buy

61.32%

Upside

Assigned

03/05/26

Analysts Offer Insights on Healthcare Companies: Stevanato Group (NYSE: STVN), Stryker (NYSE: SYK) and Xencor (NASDAQ: XNCR)

Michael Ryskin

Bank of America Securities

€26.01→€24.28

Buy

41.16%

Upside

Reiterated

03/04/26

Stevanato Group price target lowered to $28 from $30 at BofAStevanato Group price target lowered to $28 from $30 at BofA

David Windley

Jefferies

€19.94→€15.17

Hold

-11.78%

Downside

Reiterated

02/10/26

Stevanato Group price target lowered to $17.50 from $23 at JefferiesStevanato Group price target lowered to $17.50 from $23 at Jefferies

Dan Leonard

RBC Capital

€22.54→€24.28

Hold

41.16%

Upside

Reiterated

08/06/25

UBS Sticks to Its Hold Rating for Stevanato Group (STVN)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

MLYSMineralys Therapeutics, Inc.

AMLXAmylyx Pharmaceuticals Inc

ZURAZura Bio

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Stevanato Group

3 Months

Matt LarewWilliam Blair

Success Rate

10/11 ratings generated profit

Average Return

+9.68%

Copying Matt Larew's trades and holding each position for 3 Months would result in 90.91% of your transactions generating a profit, with an average return of +9.68% per trade.

1 Year

Patrick B DonnellyCiti

Success Rate

8/12 ratings generated profit

Average Return

+16.31%

Copying Patrick B Donnelly's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +16.31% per trade.

2 Years

Paul KnightKeyBanc

Success Rate

4/7 ratings generated profit

Average Return

+21.74%

Copying Paul Knight's trades and holding each position for 2 Years would result in 57.14% of your transactions generating a profit, with an average return of +21.74% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

87N Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 87N has received 7 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. 87N average Analyst price target in the past 3 months is 19.73.

Each month's total comprises the sum of three months' worth of ratings.

87N Financial Forecast

87N Earnings Forecast

Next quarter’s earnings estimate for 87N is €0.13 with a range of €0.12 to €0.13. The previous quarter’s EPS was €0.11. 87N beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.80% of the time in the same period. In the last calendar year 87N has Performed in-line its overall industry.

87N Sales Forecast

Next quarter’s sales forecast for 87N is €298.22M with a range of €293.00M to €301.23M. The previous quarter’s sales results were €277.53M. 87N beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.18% of the time in the same period. In the last calendar year 87N has Performed in-line its overall industry.

87N Stock Forecast FAQ

What is DE:87N’s average 12-month price target, according to analysts?

Based on analyst ratings, Stevanato Group’s 12-month average price target is 19.73.

What is DE:87N’s upside potential, based on the analysts’ average price target?

Stevanato Group has 14.69% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Stevanato Group a Buy, Sell or Hold?

Stevanato Group has a consensus rating of Strong Buy, which is based on 4 buy ratings, 1 hold ratings and 0 sell ratings.

What is Stevanato Group’s share price target?

The average share price target for Stevanato Group is 19.73. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €22.54 ,and the lowest forecast is €16.48. The average share price target represents 14.69% Increase from the current price of €17.2.

What do analysts say about Stevanato Group?

Stevanato Group’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of Stevanato Group?

To buy shares of DE:87N, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Stevanato Group (87N) Stock Forecast & Price Target

87N Analyst Ratings

87N Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Stevanato Group

87N Analyst Recommendation Trends

87N Financial Forecast

87N Earnings Forecast

87N Sales Forecast

87N Stock Forecast FAQ

Detailed List of Analyst Forecasts